Uncategorized

CHAI’s standards fill a gap left by the federal government as the private sector continues to race ahead on AI.

BTIG analysts said the company’s near-term cash needs, “disappointing sales results and lack of progress on profitability metrics” are concerning.

A National Bureau of Economic Research report found layoffs followed hospital mergers, as employers struggled to absorb the costs of rising healthcare premiums.

Experts expect the release of new over-the-counter glucose monitors in the U.S. to fuel more widespread use of the devices.

The deal is set to close later this year, pending regulatory review.

Zimvie is reportedly working with an adviser to assess its options after strategic investors and industry players showed interest in a deal.

Zealand Pharma is looking to build on last week’s positive Phase Ib trial results by raising around $1 billion in a public offering, with the proceeds being used to advance its obesity candidates.

After back-to-back failures in 2021, Wave Life Sciences has finally aced a Phase Ib/IIa Huntington’s disease trial and is looking to a potential accelerated approval for its investigational antisense oligonucleotide.

This week, we discuss the expanded approval of Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys, Alnylam’s high stakes ATTR-CM win and highlights from ADA.

El síndrome de ovario poliquístico es uno de los trastornos endocrinos más comunes que afectan a las mujeres en edad reproductiva. Se caracteriza por niveles elevados de andrógenos (hiperandrogenemia) y está asociado con una amplia gama de impactos sobre la salud, …